TerrAscend (TSNDF) Asset Writedowns and Impairment (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Asset Writedowns and Impairment of $239000.0 for Q1 2026, down 50.21% year-over-year from $480000.0 in Q1 2025, and down 64.7% quarter-over-quarter from $677000.0 in Q4 2025.
TerrAscend (TSNDF) Asset Writedowns and Impairment (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Asset Writedowns and Impairment for 6 consecutive years, with $239000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment fell 50.21% year-over-year to $239000.0; the TTM figure through Mar 2026 stood at $1.4 million (down 70.56% YoY), while the FY2025 annual figure was $1.7 million, down 45.48% from the prior year.
- Asset Writedowns and Impairment slipped to $239000.0 in Q1 2026 per TSNDF's latest filing, from $677000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $152.9 million in Q3 2022 and bottomed at -$7.3 million in Q4 2022.
- Historically, Asset Writedowns and Impairment has averaged $9.2 million across 5 years, with a median of $314000.0 in 2025.
- On a YoY basis, Asset Writedowns and Impairment climbed as much as 39314.43% in 2022 and fell as far as 572.06% in 2022.
- TerrAscend's Asset Writedowns and Impairment stood at -$7.3 million in 2022, then surged by 90.04% to -$728000.0 in 2023, then soared by 675.55% to $4.2 million in 2024, then sank by 83.84% to $677000.0 in 2025, then sank by 64.7% to $239000.0 in 2026.
- Business Quant data shows TSNDF's Asset Writedowns and Impairment at $239000.0 in Q1 2026, $677000.0 in Q4 2025, and $314000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | TerrAscend | 187.35 Mn | 145.23 Mn | 36.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 587,000.00 |
| Jun 30, 2026 | 587,000.00 |
| Mar 31, 2026 | 239,000.00 |
| Mar 31, 2026 | 239,000.00 |
| Dec 31, 2025 | 677,000.00 |
| Dec 31, 2025 | 677,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Jun 30, 2025 | 193,000.00 |
| Jun 30, 2025 | 193,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Dec 31, 2024 | 4.19 Mn |
| Dec 31, 2024 | 4.19 Mn |
| Sep 30, 2024 | 183,000.00 |
| Sep 30, 2024 | 183,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | 2.44 Mn |
| Mar 31, 2024 | 2.44 Mn |